2024-06-18 03:42:39 ET
Summary
- Moderna's RSV vaccine has been approved by the FDA, but it faces competition from GSK and PFE's offerings.
- A June 26 meeting of the Advisory Committee on Immunization Practices is a near-term catalyst. MRNA is hoping for parity with GSK/PFE when it comes to recommendations for RSV vaccines.
- With regards to differentiation, MRNA's RSV vaccine comes as a pre-filled syringe, which could help it to carve out its share of the market.
...
Read the full article on Seeking Alpha
For further details see:
Moment Of Truth Approaches For Moderna's RSV Vaccine